Oct 10 2008, 9:02 AM EST
News source: Business Wire
Synageva BioPharma announced today the appointment of Mark
Goldberg, M.D., Senior Vice President of Clinical Research at Genzyme
Corp., and a leading medical oncologist and hematologist, to the
Company's Board of Directors.
"In addition to his accomplished medical background, Mark is a
seasoned industry executive and his direct experience in overseeing
the development of Genzyme's products will make his strategic guidance
an invaluable asset to the Synageva Board," said Felix J. Baker,
Ph.D., Chairman of the Synageva Board and Managing Partner at Baker
Brothers Investments.
"Having worked very closely with Dr Goldberg for almost 10 years
at Genzyme, I am confident Mark will provide critical insight into the
execution of our clinical development and product commercialization
strategies," said Sanj K. Patel, President and Chief Executive Officer
at Synageva. "Our proprietary Protein Expression System is enabling us
to generate a diverse pipeline of follow-on, next-generation and novel
monoclonal antibodies, cytokines and other biopharmaceuticals. These
products are intended for use in a variety of therapeutic areas such
as oncology, autoimmune and metabolic disorders. Mark's extensive
clinical development experience in these areas and others will be
instrumental as Synageva provides alternative and improved products
for patients around the world."
Mark Goldberg, M.D., first joined Genzyme in 1996 as Medical
Director for Oncology and following several promotions, has held his
current position of Senior Vice President Clinical Research since
2000. Dr. Goldberg is a board-certified medical oncologist and
hematologist. Prior to working at Genzyme, he was a full-time staff
physician at Brigham and Women's Hospital and Dana Farber Cancer
Institute, where he still holds appointments. Dr. Goldberg is an
Associate Professor of Medicine at Harvard Medical School and is an
author on more than 50 published papers. Dr. Goldberg received his
A.B. (magna cum laude) from Harvard College and his M.D. (cum laude)
from Harvard Medical School.
About Synageva BioPharma
Synageva BioPharma is focused on the development of
biopharmaceuticals that address the needs of a global patient
population in multiple areas, including oncology, autoimmune diseases
and metabolic diseases.
Synageva(TM) has created sustainable value through its robust and
cost-effective protein expression technology, AES(TM). We have
generated a diverse pipeline of follow-on products as well as
next-generation products that may exhibit superior efficacy and safety
profiles. www.synageva.com
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All